B & T Capital Management DBA Alpha Capital Management decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,738 shares of the company’s stock after selling 1,411 shares during […]
McGuire Investment Group LLC lowered its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 58,597 shares of the company’s stock after selling 809 shares during the quarter. McGuire […]
IMA Wealth Inc. cut its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,517 shares of the company’s stock after selling 255 shares during the period. IMA Wealth Inc.’s […]
Federated Hermes Inc. cut its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 0.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 508,100 shares of the company’s stock after selling 658 shares during the quarter. Federated Hermes Inc. owned […]
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price target raised by Needham & Company LLC from $88.00 to $90.00 in a report issued on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock. Other research analysts also recently issued reports about the company. Royal Bank of Canada increased their […]